David Camidge is an Oncology physician affiliated with University of Colorado Cancer Center. OpenAlex indexes 56 publications with 2,513 citations (h-index 12); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 4 Jan 2011.
Clinical trials
- CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Sponsor: Criterium, Inc.
- Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
Sponsor: Symphogen A/S
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
44 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202511 payments$20,007openpaymentsdata.cms.gov ↗
- Janssen Research & Development, LLCProgram year20255 payments
- TAIHO ONCOLOGY, INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37.2%Kinase inhibitor37.2%Alecensa67%Alunbrig33%Part D<11 patientsSensory organs
37.2%Corticosteroid37.2%Dexamethasone100%Part D≥11 patientsNervous system
15%Phenothiazine15%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2008–2009 per NIH RePORTER. The latest:
- A randomized phase II study of erlotinib with or without the anti-IGF-1R monoclon
University of Colorado Denver
FY2009$348,354R21CA135595 - A randomized phase II study of erlotinib with or without the anti-IGF-1R monoclon
University of Colorado Denver
FY2008$369,078R21CA135595
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bryan Haugen, MD
University of Colorado Cancer Center
Wells Messersmith, MD
University of Colorado Cancer Center
Thomas Flaig, MD
University of Colorado Cancer Center
Christopher Lieu, MD
University of Colorado Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”